

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No 05-967-D5; (EX04-056C-US))**

In the Application of:)
Francis-Lang *et al.*)
Serial No.: 10/567,950) **Examiner: Yao, Lei**
Filing Date: June 8, 2006) **Group Art Unit: 1642**
For: PRKCs as Modifiers of the Beta-Catenin Pathway and Methods of Use) **Confirmation No. 5893**

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is filed in response to the restriction requirement mailed on November 26, 2008 in the above-mentioned application. A petition for a four month extension of time with appropriate fee is submitted herewith. It is believed that no further fee is due in connection with this filing. However, if a further fee is due the Commissioner is authorized to charge our deposit account 13-2490.

With respect to the restriction requirement, Applicants hereby elect with traverse Group II, claims 1-12 and 16-19, allegedly drawn to a method of identifying a candidate beta catenin pathway modulating agent in a system comprising a PRKC nucleic acid for prosecution on the merits. The claims readable thereon are claims 1-12 and 16-19.

With respect to the species election for a candidate beta catenin modulating agent, Applicants hereby elect a nucleic acid antisense oligomer. The claims readable thereon are claims 1-12 and 16-19. With respect to the species election for an assay system, Applicants hereby elect a cell proliferation assay. The claims readable thereon are claims 1-12 and 16-19. Upon the allowance of a generic claim, Applicants are entitled to consideration of

claims to additional species which are written in dependent form or otherwise include all of the limitations of an allowed generic claim as provided by 37 CFR 1.141.

If the Examiner has any questions regarding this response, he is invited to call the undersigned attorney.

Respectfully submitted,

Dated: April 27, 2009

/Anita J. Terpstra/
Anita J. Terpstra, Ph.D.
Registration No. 47,132